Clinical trials: Cushing Disease
Cushing Syndrome
The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
This is an observational, open, prospective multi-centre study designed to evaluate melatonin and cortisol circadian rhythm, immunological profile and anthropometric parameters in Cushing Syndrome patients during active Remission…
- Trial name
- TheHOURS (NCT03343470)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Roma La Sapienza
Cushing's Disease
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
Cushing's disease is characterized by the existence of a benign pituitary tumor developed from corticotropic cells responsible for excessive ACTH secretion.
- Trial name
- IMPEC (NCT03346954)
- Testing
- [11C]-Methionine PET/MRI
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Hypercortisolism, Type 2 Diabetes (T2DM)
Salivary Cortisol and Hypercortisolism in Type 2 Diabetes
The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies.
- Trial name
- NCT07156370
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai 6th People's Hospital
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Endocrine Disease, Diabetes
Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Background: Metabolic syndrome is a name given to a group of factors that tend to occur together. These risk factors include central obesity (extra weight around the middle of the body) and high blood pressure and blood sugar…
- Trial name
- NCT01419535
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Disease
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
Background: Pasireotide treatment is strictly associated with glucose metabolism impairment. The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
- Trial name
- NCT03080181
- Testing
- Pasireotide 0.6 MG/ML
- Volunteers
- 24 people
- Sponsor
- University of Palermo
Adrenal Insufficiency, Cushing Syndrome
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Cortisol is an essential for life hormone secreted in a pulsatile pattern on a diurnal rhythm. Given the complexity of cortisol secretion on a circadian rhythm with pulsations, current methods of cortisol measurement have…
- Conditions
- Adrenal Insufficiency, Cushing Syndrome, Hyperaldosteronism
- Trial name
- SensoCort (NCT06008184)
- Testing
- 24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva), 24 hours sampling of ISF or sweat (after validating the correlation with blood)
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Cushing Disease
Cushing´s Disease Epidemiology in Sweden
The purpose of this study is to study since 1987 all patients diagnosed with CD in Sweden and determine their outcomes including mortality.
- Trial name
- NCT02350153
- Where
- Sweden
- Volunteers
- 502 people
- Sponsor
- Vastra Gotaland Region
Cushing Syndrome, Adrenocortical Carcinoma
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC) is an extremely rare disease. Approximately 50% of ACC in adults are functioning leading to hormonal and metabolic syndromes.
- Trial name
- ABACUS (NCT03145285)
- Testing
- Abiraterone Acetate
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Endocrine Diseases
Evaluation of Adults With Endocrine and Metabolic-Related Conditions
Background: There are many endocrine and metabolic-related conditions. Two well-known disorders include diabetes and thyroid disease. Some of these diseases are caused by a change in genes.
- Trial name
- NCT02830308
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy, Involutional Depression
Dynamics of Leptin and Endocrine Function
This is a study investigating the hormones and substances important to the stress response. The hormone that is most directly responsible for stress response is called corticotropin-releasing hormone (CRH).
- Trial name
- NCT00001543
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Hypercortisolism
Effects of Metyrapone in Patients With Hypercortisolism
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers…
- Trial name
- CEM (NCT05255900)
- Testing
- Metyrapone Capsules
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Auxologico Italiano
Pituitary Neoplasm
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Background: Cushing s disease can be caused by a tumor of the pituitary gland, a small gland about the size of a pea located at the base of the brain.
- Trial name
- NCT01459237
- Testing
- Acthrel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cushings Disease
Treatment of Cushing's Disease With R-roscovitine
The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.
- Trial name
- NCT02160730
- Testing
- R-roscovitine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shlomo Melmed, MD
Cushing Syndrome, Cushing Disease
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an…
- Conditions
- Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
- Trial name
- NCT05804669
- Testing
- atumelnant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Adrenal Insufficiency, Congenital Adrenal Hyperplasia
Dynamic Hormone Diagnostics in Endocrine Disease
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary…
- Conditions
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome, Growth Hormone Deficiency
- Trial name
- ultradian (NCT02934399)
- Testing
- 27 hour subcutaneous fluid sampling
- Where
- 4 sites in Greece, Norway and 2 more
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
Cushing Syndrome, Neoplasms
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.
- Trial name
- NCT05347979
- Testing
- Dabigatran Etexilate, Relacorilant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics